Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M
Division of General Pediatrics, Schneider Children's Hospital, New Hyde Park, NY 11042, USA.
J Perinatol. 2008 Jul;28(7):511-7. doi: 10.1038/jp.2008.28. Epub 2008 Mar 27.
The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Prospective observational registry enrolling those who received >or=1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Of 19 548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.
帕利珠单抗疗效登记处收集了接受帕利珠单抗预防引起严重下呼吸道疾病的呼吸道合胞病毒（RSV）的婴幼儿数据。
前瞻性观察登记研究，纳入在2000年至2004年任何RSV流行季节期间在美国参与研究的机构接受≥1剂帕利珠单抗的患者。
在纳入的19548名受试者中，40%在孕32周前出生，48%在孕32至35周出生，12%在孕35周后出生。危险因素包括入托、早产、慢性肺病（CLD）和先天性心脏病（CHD）。接受帕利珠单抗治疗的患者RSV住院率为1.3%。性别、孕龄<32周、CLD、CHD、先天性气道异常、严重神经肌肉疾病、医疗补助保险以及家中有>2个孩子与显著更高的住院率相关。帕利珠单抗居家预防与住院率降低相关。
主要针对高危婴儿使用帕利珠单抗预防的数据证实RSV住院率较低。
